BR112015006264A2 - composições de oligonucleotídeos cpg ocorrendo naturalmente e suas aplicações terapêuticas - Google Patents
composições de oligonucleotídeos cpg ocorrendo naturalmente e suas aplicações terapêuticasInfo
- Publication number
- BR112015006264A2 BR112015006264A2 BR112015006264A BR112015006264A BR112015006264A2 BR 112015006264 A2 BR112015006264 A2 BR 112015006264A2 BR 112015006264 A BR112015006264 A BR 112015006264A BR 112015006264 A BR112015006264 A BR 112015006264A BR 112015006264 A2 BR112015006264 A2 BR 112015006264A2
- Authority
- BR
- Brazil
- Prior art keywords
- naturally occurring
- disorders
- therapeutic applications
- combination
- oligonucleotide compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
abstract: the present invention relates to combination therapies for the treatment of a variety of disorders in mammals, including hepatic disorders and cancer. the combination of agents includes naturally-occurring (versus synthetic) oligonucleotides, particularly immunostimulatory oligodeoxynucleotides such as cpg odns, obtained from a natural source and one or more extracts from a gram positive bacteria, such as lactobacillus spp. ----------------------------------------------------------------------------------------------- tradução do resumo resumo patente de invenção: "composições de oligonucleotídeos cpg ocorrendo naturalmente e suas aplicações terapêuticas". a presente invenção refere-se a terapias de combinação para o tratamento de uma variedade de distúrbios em mamíferos, incluindo distúrbios hepáticos e câncer. a combinação de agentes inclui oligonucleotídeos ocorrendo naturalmente (versus sintéticos), particularmente oligo desoxinucleotídeos imuno estimuladores tais como odns cpg, obtidos de uma fonte natural e um ou mais extratos de uma bactéria gram positiva, tal como lactobacillus spp.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261704090P | 2012-09-21 | 2012-09-21 | |
PCT/US2013/061236 WO2014047588A1 (en) | 2012-09-21 | 2013-09-23 | Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015006264A2 true BR112015006264A2 (pt) | 2017-07-04 |
Family
ID=50339054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015006264A BR112015006264A2 (pt) | 2012-09-21 | 2013-09-23 | composições de oligonucleotídeos cpg ocorrendo naturalmente e suas aplicações terapêuticas |
Country Status (7)
Country | Link |
---|---|
US (3) | US20140086849A1 (pt) |
EP (1) | EP2898073A4 (pt) |
JP (4) | JP2015535829A (pt) |
BR (1) | BR112015006264A2 (pt) |
HK (1) | HK1213017A1 (pt) |
IL (1) | IL237865B (pt) |
WO (1) | WO2014047588A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ625592A (en) | 2012-01-16 | 2016-09-30 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatic diseases and disorders |
US20170232047A1 (en) * | 2012-01-16 | 2017-08-17 | Elizabeth McKenna | Control of Cellular Redox Levels |
EP2898073A4 (en) | 2012-09-21 | 2016-03-23 | Elizabeth Mckenna | Naturally-occurring CPG-oligonucleotide compositions and therapeutic applications thereof |
EP3554344A1 (en) | 2016-12-14 | 2019-10-23 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
US20210123057A1 (en) * | 2019-10-29 | 2021-04-29 | Northwestern University | Sequence Multiplicity Within Spherical Nucleic Acids |
CN114515295B (zh) * | 2022-03-31 | 2023-08-29 | 东莞市人民医院 | CpG ODN在制备防治药物性肝损伤的药物中的应用 |
CN115227684B (zh) * | 2022-07-28 | 2023-11-17 | 杭州师范大学 | 靶向M2型巨噬细胞CpG和ELE脂质体及制法和应用 |
CN117180317B (zh) * | 2023-11-02 | 2024-01-26 | 深圳市第二人民医院(深圳市转化医学研究院) | 詹氏乳杆菌来源纳米囊泡在制备防治卵巢早衰治疗药物中的应用 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3806290A (en) | 1972-07-12 | 1974-04-23 | Warner Lambert Co | Apparatus for center-filled chewing gum |
US4322405A (en) | 1981-04-06 | 1982-03-30 | Laboratoires Om Societe Anonyme | Method for treating rheumatoid arthritis |
JPH04264034A (ja) | 1991-02-18 | 1992-09-18 | Snow Brand Milk Prod Co Ltd | 生体内過酸化脂質抑制剤 |
US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
IT1254210B (it) | 1992-02-10 | 1995-09-14 | Simone Claudio De | Composizioni dietetiche e/o farmaceutiche a base di batteri lattici liofilizzati, loro preparazione e impiego |
US5716615A (en) | 1992-02-10 | 1998-02-10 | Renata Maria Anna Cavaliere Vesely | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
CA2560114A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
IT1283225B1 (it) | 1996-03-11 | 1998-04-16 | Renata Maria Anna Ve Cavaliere | Ceppi di batteri, composizione farmaceutica contenente uno o piu' di tali ceppi e uso dei medesimi per la prevenzione e la terapia delle |
JPH09301878A (ja) | 1996-05-13 | 1997-11-25 | Youshindou:Kk | 腫瘍増殖抑制剤 |
JPH09301877A (ja) | 1996-05-13 | 1997-11-25 | Youshindou:Kk | 肝炎治療・予防剤 |
AR022986A1 (es) | 1996-08-12 | 2002-09-04 | Gist Brocades Bv | Produccion y uso de composiciones que comprenden concentraciones altas de actividad de vitamina b12 |
AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
WO1998040100A1 (en) | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
CA2301575C (en) | 1997-05-20 | 2003-12-23 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
US6281191B1 (en) | 1997-12-29 | 2001-08-28 | Vladimir I. Slesarev | Compositions and methods for treating hepatitis-C |
EP1067956B1 (en) | 1998-04-03 | 2007-03-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
JP4074006B2 (ja) * | 1998-06-24 | 2008-04-09 | アサマ化成株式会社 | IgE抗体産生抑制物質の製造方法並びにそれを用いた食品 |
JP2000262247A (ja) * | 1999-03-19 | 2000-09-26 | Asama Kasei Kk | 免疫調節剤、免疫調節食品および免疫調節飼料 |
EP1178118A1 (en) | 2000-08-02 | 2002-02-06 | Dsm N.V. | Isolation of microbial oils |
WO2002069939A2 (en) | 2001-03-05 | 2002-09-12 | Ortho-Mcneil Pharmaceutical, Inc. | Taste masked pharmaceutical compositions |
JP3853673B2 (ja) | 2001-03-09 | 2006-12-06 | 森永乳業株式会社 | C型慢性肝炎治療剤 |
WO2003015711A2 (en) | 2001-08-17 | 2003-02-27 | Coley Pharmaceutical Group, Inc. | Combination motif immune stimulatory oligonucleotides with improved activity |
US20030119774A1 (en) * | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
GB0203306D0 (en) | 2002-02-12 | 2002-03-27 | Norferm Da | Method |
JP2006507362A (ja) * | 2002-10-22 | 2006-03-02 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 癌転移の活性な特異的免疫治療法 |
KR20050065661A (ko) | 2002-11-01 | 2005-06-29 | 비로파마 인코포레이티드 | 벤조푸란 화합물, 조성물 및 c형 간염 바이러스 감염 및관련 질병의 치료 및 예방 방법 |
US7674467B2 (en) | 2003-09-03 | 2010-03-09 | Intralytix, Inc. | Salmonella bacteriophage and uses thereof |
JP3976742B2 (ja) * | 2004-02-27 | 2007-09-19 | 江守商事株式会社 | インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド |
JP2005247780A (ja) | 2004-03-05 | 2005-09-15 | Masakazu Maruyama | ウイルス性肝炎治療剤 |
KR20080034973A (ko) | 2005-07-29 | 2008-04-22 | 산또리 가부시키가이샤 | 후코이단 또는 후코이단 가수분해 생성물과 면역 부활소재를 함유하는 조성물 |
DK1991678T4 (da) | 2006-02-15 | 2020-10-19 | Rechtsanwalt Thomas Beck | Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer |
EP1872792A1 (en) | 2006-06-29 | 2008-01-02 | Biotech Tools S.A. | A method for the production of hydrolyzed allergen |
US8007783B2 (en) * | 2006-08-22 | 2011-08-30 | Carl Miller | Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine |
US8304226B2 (en) | 2006-08-22 | 2012-11-06 | Carl Miller | Quality of life of hepatitis C patients with a formulation for administration to the oral mucosa including freeze dried lysate of selected Lactobacillus or Bifidobacterium species and N-acetyl D-glucosamine |
DE202008006598U1 (de) * | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
WO2010001509A1 (ja) * | 2008-07-04 | 2010-01-07 | 日本ハム株式会社 | イムノグロブリンa誘導能の高い新規乳酸菌 |
KR20110051268A (ko) * | 2008-09-04 | 2011-05-17 | 오엠 파르마 | 락토바실러스 박테리아 유래 면역조절 추출물 및 이의 제조 방법 및 이의 용도 |
AU2010262738A1 (en) | 2009-05-20 | 2011-10-13 | Lingual Consegna Pty Ltd | Buccal and/or sublingual therapeutic formulation |
JP6019492B2 (ja) * | 2009-08-28 | 2016-11-02 | 国立大学法人 千葉大学 | 乳酸菌および抗原物質を含み、口腔内に投与されることを特徴とする抗アレルギー剤 |
FR2951377B1 (fr) | 2009-10-21 | 2012-06-22 | Oreal | Association d'un lysat de probiotique et d'un derive c-glycoside |
GB201009273D0 (en) * | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
NZ625592A (en) * | 2012-01-16 | 2016-09-30 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatic diseases and disorders |
EP2898073A4 (en) | 2012-09-21 | 2016-03-23 | Elizabeth Mckenna | Naturally-occurring CPG-oligonucleotide compositions and therapeutic applications thereof |
-
2013
- 2013-09-23 EP EP13840019.7A patent/EP2898073A4/en not_active Ceased
- 2013-09-23 JP JP2015533259A patent/JP2015535829A/ja active Pending
- 2013-09-23 WO PCT/US2013/061236 patent/WO2014047588A1/en active Application Filing
- 2013-09-23 US US14/034,044 patent/US20140086849A1/en not_active Abandoned
- 2013-09-23 BR BR112015006264A patent/BR112015006264A2/pt not_active Application Discontinuation
-
2015
- 2015-03-06 US US14/640,075 patent/US9931398B2/en active Active
- 2015-03-22 IL IL237865A patent/IL237865B/en active IP Right Grant
-
2016
- 2016-01-28 HK HK16100967.1A patent/HK1213017A1/zh unknown
-
2017
- 2017-12-08 JP JP2017236070A patent/JP2018076339A/ja not_active Withdrawn
-
2018
- 2018-01-04 US US15/862,209 patent/US10688177B2/en active Active
-
2019
- 2019-12-27 JP JP2019237668A patent/JP2020090503A/ja active Pending
-
2022
- 2022-02-14 JP JP2022020362A patent/JP2022078078A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20170266277A9 (en) | 2017-09-21 |
US9931398B2 (en) | 2018-04-03 |
EP2898073A4 (en) | 2016-03-23 |
EP2898073A1 (en) | 2015-07-29 |
US20180369367A1 (en) | 2018-12-27 |
IL237865B (en) | 2021-04-29 |
WO2014047588A1 (en) | 2014-03-27 |
US20170087247A1 (en) | 2017-03-30 |
JP2018076339A (ja) | 2018-05-17 |
US20140086849A1 (en) | 2014-03-27 |
JP2020090503A (ja) | 2020-06-11 |
HK1213017A1 (zh) | 2016-06-24 |
JP2015535829A (ja) | 2015-12-17 |
JP2022078078A (ja) | 2022-05-24 |
IL237865A0 (en) | 2015-05-31 |
US10688177B2 (en) | 2020-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015006264A2 (pt) | composições de oligonucleotídeos cpg ocorrendo naturalmente e suas aplicações terapêuticas | |
PH12019502725A1 (en) | Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety | |
BR112012022755A2 (pt) | composição com bactérias probióticas para uso no tratamento de distúrbios imunológicos | |
BR112012014066A2 (pt) | preparações de combinações com exossomos e corticosteróide | |
EP2563366A4 (en) | USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS | |
UA109112C2 (uk) | Короткотривала високотемпературна обробка, що дозволяє одержати мікробні препарати із протизапальними профілями | |
UA105033C2 (uk) | Фармацевтична композиція, що включає глюкопіранозилзаміщене похідне бензолу, фармацевтична дозована форма, що містить зазначене похідне, їх застосування для лікування метаболічного порушення | |
BR112015024846A2 (pt) | composições para utilização no estímulo do crescimento ósseo | |
MX2016009898A (es) | Tratamientos para acne resistente. | |
MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
CR20120202A (es) | Métodos y composiciones para tratar cáncer | |
WO2012112777A3 (en) | Biosynthesis of human milk oligosaccharides in engineered bacteria | |
BR112015007878A2 (pt) | composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos | |
EP2405918A4 (en) | PREBIOTIC OLIGOSACCHARIDE | |
MX357528B (es) | Metodos para el tratamiento de trastornos metabolicos usando intercambiadores epimetabolicos, moleculas intracelulares multidimensionales o influencias ambientales. | |
NZ603901A (en) | Vectors and sequences for the treatment of diseases | |
BR112015015898A8 (pt) | composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
EP2493464A4 (en) | METHYLSULFONYLMETHANE (MSM) FOR THE TREATMENT OF DRUG-RESISTANT MICROORGANISMS | |
PL2134704T3 (pl) | Związki i kompozycje pełniące rolę modulatorów aktywności GPR119 | |
MX2012013731A (es) | Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas. | |
MX2011009751A (es) | Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2. | |
BR112015006055A2 (pt) | composições e métodos para o tratamento e prevenção de lesão tecidual e doença | |
BR112013001838A2 (pt) | formulações contendo extratos de echinacea angustifólia e zingiber officinale que são úteis na redução de inflamação e dor periférica | |
MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |